Abstract
Introduction
In 2008, seven major market sales of anticonvulsants reached $13.6 billion,
making it one of the largest therapeutic drug classes in the Pharmaceutical
sector. However, generic incursion of second generation anticonvulsants will
continue to increase the barrier to entry for prospective players, although
viable commercial opportunities exist to optimize returns from this lucrative
drug class market
Scope of this research
- In-depth analysis of the current and future anticonvulsant drug class
market across the US, Japan, France, Germany, Italy, Spain and the UK.
- Country-specific total brand sales forecasts for key products, generics
and pipeline agents across the seven major markets to 2018.
- Assessment of the main opportunities and threats present in the
anticonvulsant market, with analysis of trends in emerging markets.
- Evaluation of the indication expansion strategies employed by leading
anticonvulsant players, such as Pfizer, GlaxoSmithKline, and Johnson & Johnson.
Research and analysis highlights
Bipolar disorders, migraine prophylaxis, fibromyalgia and neuropathic pain
represent the most attractive indication expansion opportunities for
anticonvulsant developers, providing blockbuster revenues. Strong growth in
non-epilepsy conditions will see Pfizer' s Lyrica (pregabalin) become the
market leading brand by 2018.
Several leading anticonvulsant brands have reached the end of their lifecycle
in the US and EU. In an attempt to offset revenue decline, marketers are
looking towards geographical expansions. Due to reduced competition, Japan
represents an attractive market as are emerging markets.
UCB' s Keppra' s (levetiracetam) is the leading treatment for epilepsy. Despite
the recent launch of two further anticonvulsants and the presence of a
late-stage pipeline candidate, generic erosion of Keppra will cause UCB' s
position in the anticonvulsant market to decline between 2009 and 2018.
Key reasons to purchase this research
- Quantify the performance of key marketed and pipeline anticonvulsant drugs
in the seven major markets over the period 2008 to 2018.
- Assess the changing key opportunities and threats affecting current market
players and prospective new entrants.
- Identify the leading brands in this drug class over the next 10 years and
understand the key factors driving their success.
| 
View Cart
